LBF20207PG26: Difference between revisions
No edit summary |
No edit summary |
(No difference)
| |
Revision as of 10:00, 25 February 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1511 |
| LipidMaps | LMFA03010026 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG26 |
| 15-KETOPROSTAGLANDIN F_2α | |
|---|---|
| |
| Structural Information | |
| 7- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3-oxo-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid | |
| |
| 15-KETO-PGF2 alpha | |
| Formula | C20H32O5 |
| Exact Mass | 352.224974134 |
| Average Mass | 352.46508 |
| SMILES | C(CCC(=O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](C[C@@H]1O)O)CC |
| Physicochemical Information | |
| 15-Keto-prostaglandin F2 alpha is the oxidized product of prostaglandin F2 alpha by 15-hydroxyprostaglandin dehydrogenase, which is present in lung, kidney, placenta and other tissues and catalyzes the NAD- or NADP-dependent dehydrogenation of 15-dydroxyl group Hansen_HS . | |
| 15-Keto-prostaglandin F2 alpha is further metabolized by its Delta 13-reduction, beta -oxidation and omega oxidation. The ultimate metabolite is 5 alpha ,7 alpha -dihydroxy-11-keto-tetranorprosta-1,16-dioic acid, and excreted in urine Granstrom_E et al.. | |
| It is well known that the biological activities of various prostaglandins are reduced upon their dehydrogenation at carbon-15 by the catalysis of 15-hydroxyprostaglandin dehydrogenase Anggard_E . | |
| cDNA for placental 15-hydroxyprostaglandin dehydrogenase was cloned Ensor_CM et al.. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
